PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge

• Egile Nagusiak: Thomas Southworth (Egilea), Sarah Mason (Egilea), Alan Bell (Egilea), Isabel Ramis (Egilea), Marta Calbet (Egilea), Anna Domenech (Egilea), Neus Prats (Egilea), Montserrat Miralpeix (Egilea), Dave Singh (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2018-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Inhaled allergen challenges are often used to evaluate novel asthma treatments in early phase clinical trials. Current novel therapeutic targets in asthma include phosphoinositide 3-kinases (PI3K) delta and gamma, p38 mitogen-activated protein kinase (p38) and Janus kinase/Signal...